<DOC>
	<DOCNO>NCT01426243</DOCNO>
	<brief_summary>Main objective : To develop tools evaluation humoral cell-mediated immunity Yellow Fever Vaccine ( YFV ) compare virological immune response HIV-positive HIV-negative individual give YFV . Secondary objective : - To develop assess ELISPOT technology yellow fever measure response within 7 , 14 , 28 , 90 365 day administration YFV 30 HIV negative subject 40 HIV positive subject ( CD4 &gt; 350/mm3 Highly Active Antiretroviral Therapy ( HAART ) least one year , viral load &lt; 50 copies/mL since least 6 month ) term : ( 1 ) seroconversion fluorescence , ( 2 ) cytotoxic response ELISPOT , ( 3 ) neutralize antibody level Plaque reduction neutralization test ( PRNT : reference method ) new pseudotype base method , ( 4 ) post-vaccination viremia ( 5 ) diversity viral quasi-species . - To assess impact YFV T-lymphocyte response HIV ELISPOT viral load .</brief_summary>
	<brief_title>The Yellow Fever Vaccine Immunity HIV Infected Patients : Development New Assays Virological Immunological Monitoring HIV Infected Patient .</brief_title>
	<detailed_description>Method : Clinical Trial Phase III , Multicentre protocol Saint-Louis hospital , Bichat hospital Cochin-Pasteur hospital , CERVI , INSERM U 941 SC10 collaboration . Trial treatment : Yellow fever vaccination ( STAMARIL ) Criterion : Immuno-virologic : At J-7 , J7 , J28 , M3 M12 determine level antibody fluorescence , J0 , J7 , J28 , M3 M12 title neutralization Prnt pseudotypes , ELISPOT response anti-yellow fever , viremia quantitative analysis nucleotide sequence phylogenetic strain viremia . Titles Amariles kinetics viremia , neutralize antibody ELISPOT consider surrogate marker response term group . Clinical biological tolerance : At follow measure incidence CDC classification event ( HIV+ ) general local reaction degree ≥ 2 set injection STAMARIL® . Schedule : Date first enrolment : third quarter 2011 . Inclusion period : 18 month . For subject , participation trial 12 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Yellow Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Group 1 : Voluntary HIV positive subject Adults HAART least one year ( stable treatment least 3 month prior enrolment ) &gt; 350 CD4/mm3 ( half nadir &lt; 200 CD4/mm3 ) viral load &lt; 50 copies/mL least 6 month . Patients HCV negative nonreplicative treat least 2 year normal ALT negative HBs antigen . Previous vaccination yellow fever yellow fever Fluorescence antiIgG positive . Administration immunoglobulins &lt; 3 month vaccine &lt; 1 month . Pregnancy ongoing plan study . Coinfection HCV virus untreated . HBs Ag positive . Hypersensitivity reaction egg / chicken protein ; hereditary fructose intolerance . Immunosuppression , whether congenital , idiopathic result corticosteroid systemically ( dos ≥ 20mg/d prednisone ) , due radiation antineoplastic old 6 month . History thymic dysfunction ( include thymoma thymectomy ) . For HIV + subject : ART Celsentri antiCCR5 . Group 2 : HIV negative subject HIV HCV negative Previous vaccination yellow fever yellow fever Fluorescence antiIgG positive . Administration immunoglobulins &lt; 3 month vaccine &lt; 1 month . Other vaccination defer beyond M3 . Pregnancy ongoing plan study . Coinfection HCV virus untreated . HBs Ag positive . Hypersensitivity reaction egg / chicken protein ; hereditary fructose intolerance . Immunosuppression , whether congenital , idiopathic result corticosteroid systemically ( dos ≥ 20mg/d prednisone ) , due radiation antineoplastic old 6 month . History thymic dysfunction ( include thymoma thymectomy ) . For HIV + subject : ART Celsentri antiCCR5 , coinfection HCV virus untreated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>